Meropenem resistance in salmonella typhi in a paediatric patient, Lahore, Pakistan
Journal of the Pakistan Medical Association · 28.05.2026 · 76 (06) · 986-986
DOI: 10.47391/jpma.32362 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Pakistan Medical Association, online erschienen am 28.05.2026. Verfasst von Sami Ahmad und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics, Chaudhry Muhammad Akram Teaching and Research Hospital, Lahore, Pakistan. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Dear Editor, We report a concerning case of meropenem-resistant Salmonella Typhi in a 5-year-old girl in Lahore, Pakistan, signalling an emerging threat to typhoid treatment. The patient presented with a 10-day history of fever and abdominal pain and wasdiagnosed with extensively drug-resistant (XDR) S. Typhi via blood culture. Initial treatment with meropenem (500 mg thrice daily) failed, with persistent fever and elevated C-reactive protein (268 mg/L). Clinical and Laboratory Standards Institute (CLSI)-compliant disc diffusion revealed meropenem resistance (MIC >32 µg/mL); molecular testing was not available. Combination therapy with colistin (40 mg twice daily) and azithromycin (20 mg/kg/day) resulted in defervescence within 4 days, and she was discharged from hospital after 14 days. Patient data were anonymized, and guardian consent was obtained. Meropenem is a last-resort antibiotic for XDR S. Typhi, which constitutes approximately 25% of typhoid cases in Pakistan (95% CI, 12–44%)[1]. National surveillance indicates meropenem resistance remains rare (around 2%)[1], This case, reported in Lahore, follows a documented case of NDM-5-mediated resistance in Peshawar [2]. The high prevalence of XDR strains in paediatric populations creates significant treatment challenges [3]. The emergence of resistant cases in multiple cities suggests potential plasmid-mediated spread, likely driven by antimicrobial overuse. [1,2]. We urge enhanced antimicrobial stewardship, molecular surveillance for resistance genes, and expanded typhoid conjugate vaccine coverage, which has been shown to be more than 80% effectivein Pakistani children [4]. This case underscores the need for combination therapies and vigilant monitoring to preserve meropenem’s efficacy.
Autor:innen und Institutionen
- Department of Paediatrics, Chaudhry Muhammad Akram Teaching and Research Hospital, Lahore, Pakistan.
Zitieren
APA
Ahmad, S., & Siddiq, N. (2026). Meropenem resistance in salmonella typhi in a paediatric patient, Lahore, Pakistan. Journal of the Pakistan Medical Association, 76(06), 986-986. https://doi.org/10.47391/jpma.32362
Vancouver
Ahmad S, Siddiq N. Meropenem resistance in salmonella typhi in a paediatric patient, Lahore, Pakistan. Journal of the Pakistan Medical Association. 2026;76(06):986-986. doi:10.47391/jpma.32362
BibTeX
@article{Ahmad2026,
author = {Ahmad, Sami and Siddiq, Nadia},
title = {Meropenem resistance in salmonella typhi in a paediatric patient, Lahore, Pakistan},
journal = {Journal of the Pakistan Medical Association},
year = {2026},
volume = {76},
number = {06},
pages = {986--986},
doi = {10.47391/jpma.32362}
}
EUVIMED